PRESS RELEASE
1 March 2022

Khurana And Khurana (K&K) Advises Medikabazaar On Its Series C Funding

Ka
Khurana and Khurana

Contributor

K&K is among leading IP and Commercial Law Practices in India with rankings and recommendations from Legal500, IAM, Chambers & Partners, AsiaIP, Acquisition-INTL, Corp-INTL, and Managing IP. K&K represents numerous entities through its 9 offices across India and over 160 professionals for varied IP, Corporate, Commercial, and Media/Entertainment Matters.
K&K advised Medikabazaar on IP Law issues during its highest fundraising in the B2B healthcare space.
India

Khurana and Khurana acted as the IP Counsel for Medikabazaar on its recent funding round where the Company, a leading B2B health-tech entity, raised $75 million in its Series C funding round that was led by CREAEGIS along with CDC Group.

K&K advised Medikabazaar on IP Law issues during its highest fundraising in the B2B healthcare space. Reportedly, following the completion of funding, valuation of the company soared to $260 million, aiming at 300% growth through FY22.

Existing Investors who participated include Belgium-based Ackermans & van Haaren (AvH), HealthQuad Advisors Private Limited, Japan-based Rebright Partners, Continental Europe-based Kois Holdings, and Sumitomo Mitsui Financial Group.

Subject to the regulations, Medikabazaar will use the fund for its digital capabilities; deepen the supply ecosystem & technology-driven distribution channel. Previously, Medikabazaar has raised $15.8 million in its Series B funding in 2019.

The advisory team from K&K included Tarun Khurana and Abhijeet Deshmukh.

PRESS RELEASE
1 March 2022

Khurana And Khurana (K&K) Advises Medikabazaar On Its Series C Funding

India

Contributor

K&K is among leading IP and Commercial Law Practices in India with rankings and recommendations from Legal500, IAM, Chambers & Partners, AsiaIP, Acquisition-INTL, Corp-INTL, and Managing IP. K&K represents numerous entities through its 9 offices across India and over 160 professionals for varied IP, Corporate, Commercial, and Media/Entertainment Matters.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More